Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.49 |
| ▸ | HTR2A | P28223 | 14/20 | 0.49 |
| ▸ | HTR2C | P28335 | 13/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31677818 | 0.86 | MCHR1 (0.64) | MCHR1HTR2AHTR2CABL1KCNH2 | |
| SCHEMBL31677691 | 0.86 | HTR2A (0.50) | MCHR1HTR2AHTR2C | |
| SCHEMBL31677751 | 0.86 | HTR2A (0.59) | HTR2AHTR2C | |
| SCHEMBL31677756 | 0.85 | HTR2A (0.49) | MCHR1HTR2AHTR2CABL1KCNH2 | |
| SCHEMBL31678098 | 0.85 | MCHR1 (0.52) | MCHR1HTR2AHTR2C | |
| SCHEMBL31677830 | 0.84 | MCHR1 (0.61) | MCHR1HTR2AHTR2CKCNH2 | |
| SCHEMBL31677802 | 0.84 | HTR2A (0.59) | MCHR1HTR2AHTR2CABL1KCNH2 | |
| SCHEMBL31677845 | 0.84 | HTR2A (0.49) | MCHR1HTR2AHTR2C | |
| SCHEMBL31677743 | 0.84 | HTR2A (0.57) | MCHR1HTR2AHTR2CABL1KCNH2 | |
| SCHEMBL31677688 | 0.83 | HTR2A (0.55) | MCHR1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559462-B2 | Pyrimidine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250270172-A1 | Pyrimidine Derivatives As Modulators of the 5-HT2A Serotonin Receptor Useful For The Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| EP-4236937-B1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2025-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270172-A1 | Pyrimidine Derivatives As Modulators of the 5-HT2A Serotonin Receptor Useful For The Treatment of Disorders Related Thereto | HTR2A, HTR5A, HTR1A | HRH3 536/4885MCHR1 580/4885HTR2A 1/4885 |
| US-12559462-B2 | Pyrimidine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | HTR2C, HTR1A, HTR2A | HRH3 236/4885MCHR1 73/4885HTR2A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.